Coherus, Junshi: Positive Interim Results of Phase 3 Lung Cancer Trial

 – Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone –

- Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC -

- Study to be presented September 13 at IASLC 2021 World Conference on Lung Cancer -

https://finance.yahoo.com/news/coherus-junshi-biosciences-announce-positive-224100183.html